Gerald's credibility cannot afford anymore missteps like we saw in July @ Copenhagen and then at the concussion summit in NY later that month. We were all on the edge of our seats awaiting the LYMPRO data, and it never materialized. That is how we got here. I believe that Gerald has learned a valuable lesson that will not be repeated. Shareholders are supportive of the vision of AMBS and its BOD and BOA, but the pps is not going to move appreciably without substantive news. If you announce a date for the release of news, it's got to be there period. There are those in the "know" who have seen much more than any of us has seen, and based on what they saw, LPC opened their checkbook. That same confidence was reverberating at the ACM in San Francisco a couple weeks ago as was shared by a number of shareholders in attendance. Gerald just do it!! We are ready!!
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links